GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genome & Co (XKRX:314130) » Definitions » Other Income (Expense)

Genome (XKRX:314130) Other Income (Expense) : ₩-4,253 Mil (TTM As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Genome Other Income (Expense)?

Genome's other income expense for the Genome's pretax income for the three months ended in Dec. 2024 was ₩-6,135 Mil. Its other income expense for the trailing twelve months (TTM) ended in Dec. 2024 was ₩-4,253 Mil.

Genome Other Income (Expense) Historical Data

The historical data trend for Genome's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genome Other Income (Expense) Chart

Genome Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Income (Expense)
Get a 7-Day Free Trial -3,433.67 -319.79 -1,195.96 855.15 -4,253.31

Genome Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Other Income (Expense) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3,753.61 4.82 1,847.31 29.60 -6,135.03

Genome Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-4,253 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genome  (XKRX:314130) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

Genome Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genome & Co (XKRX:314130) » Definitions » Other Income (Expense)
Comparable Companies
XKRX:067370 XKRX:049960 XKRX:185490 XKRX:046210 XKRX:383930 XKRX:388870 XKRX:378800 XKRX:261780 XKRX:365270 XKRX:348080 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
Innovalley A-801, Pangyo-ro 253, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 13486
Website
http://www.genomecom.co.kr
Genome & Co is a Korean company engaged in researching and developing dietary supplements, cosmeceuticals, and new drugs. Its products pipeline includes immunooncology therapeutic supplement for treatment of immuno-oncology, lung cancer, colorectal cancer, stomach cancer, breast cancer, pancreatic cancer; dietary supplements for treating obesity and diabetes; cosmetics used for acne and atopic dermatitis; and also produces In Virto fertilization medicine.

Genome Headlines

No Headlines